Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
29 studies found for:    "lymphangioleiomyomatosis" OR "Lymphangioleiomyomatosis"
Show Display Options
Rank Status Study
1 Recruiting National Lymphangioleiomyomatosis Registry, France
Condition: Lymphangioleiomyomatosis
Intervention:
2 Unknown  Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)
Condition: Lymphangioleiomyomatosis
Interventions: Drug: Sirolimus;   Drug: Placebo sirolimus
3 Completed Pulmonary Rehabilitation in Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Intervention: Other: Pulmonary Rehabilitation
4 Completed The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Condition: Pulmonary Lymphangioleiomyomatosis
Intervention: Drug: Saracatinib
5 Completed Trial of Aromatase Inhibition in Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Interventions: Drug: Letrozole;   Drug: Placebo
6 Completed A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Intervention: Drug: Everolimus
7 Recruiting A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Condition: Lymphangioleiomyomatosis
Intervention: Drug: Nintedanib
8 Recruiting Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Interventions: Drug: albuterol inhaler;   Procedure: PFT;   Drug: albuterol nebulizer
9 Recruiting Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Condition: Pulmonary Lymphangioleiomyomatosis
Intervention: Drug: saracatinib
10 Completed Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Intervention: Drug: sirolimus and hydroxychloroquine
11 Completed Pulmonary Hypertension in Lymphangioleiomyomatosis
Conditions: Lymphangioleiomyomatosis;   Pulmonary Hypertension
Intervention:
12 Completed Doxycycline In Lymphangioleiomyomatosis (LAM)
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis
Interventions: Drug: Doxycycline;   Drug: Placebo
13 Completed
Has Results
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Conditions: Tuberous Sclerosis Complex (TSC);   Lymphangioleiomyomatosis (LAM)
Interventions: Drug: Everolimus (RAD001);   Drug: Everolimus Placebo
14 Recruiting Safety and Durability of Sirolimus for Treatment of LAM
Condition: Lymphangioleiomyomatosis
Interventions: Drug: Sirolimus;   Drug: Everolimus
15 Recruiting Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma
Conditions: Tuberous Sclerosis;   Lymphangioleiomyomatosis;   Angiomyolipoma
Intervention:
16 Recruiting Safety of Simvastatin in LAM and TSC
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis Complex
Intervention: Drug: Simvastatin
17 Completed
Has Results
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Conditions: Lymphangioleiomyomatosis;   Lymphangiomyomas;   Pleural Effusions;   Ascites
Intervention: Drug: Octreotide
18 Unknown  Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
Conditions: Tuberous Sclerosis;   Lymphangioleiomyomatosis
Intervention: Drug: sirolimus
19 Recruiting COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
Condition: Lymphangioleiomyomatosis (LAM)
Intervention: Drug: Celecoxib
20 Completed Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
Conditions: Tuberous Sclerosis;   Lymphangioleiomyomatosis
Intervention: Drug: Rapamycin, sirolimus

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.